100 Clinical Results associated with Accredo Health Group, Inc.
0 Patents (Medical) associated with Accredo Health Group, Inc.
01 Nov 2022·Journal of Infusion Nursing
Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19
Article
Author: Miller, Christine ; Walton, Timothy P ; Prosser, Barbara
The COVID-19 pandemic changed home infusion nursing dramatically by increasing demand for home infusion nurses while decreasing their availability. Home infusion of intravenous immunoglobulin (IVIg) is an option for treatment of numerous conditions and requires considerable infusion time. Use of a higher-concentration IVIg product and shorter escalation increments may decrease required infusion time. The authors conducted a retrospective database analysis that identified 23 patients receiving IVIg before transitioning to a 10% IVIg product with a 15-minute rate escalation protocol (Gammaplex 10% IVIg) and evaluated the total infusion time before and after the transition. Among the 23 who received IVIg, the mean ± SD IVIg dose per dosing cycle before transitioning was 1.2 ± 0.7 g/kg given in 1 to 5 infusions per cycle. The mean ± SD time per infusion was 2.8 ± 0.8 hours before the transition and 2.6 ± 0.7 hours per infusion after the transition. The infusion time decreased after transition in 13 patients (56.5%), did not change in 5 patients (21.7%), and increased in 5 patients (21.7%). Nurse education on IVIg rate escalation may facilitate faster achievement of the maximum safe infusion rate and reduce infusion times. A trial transition to this 10% IVIg product with a 15-minute rate escalation protocol may also reduce infusion times.
01 May 2022·C36. HOT TOPICS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH
Impact of a Specialty Pharmacy-Prepared Infused Prostacyclin Admixture Program on Central Venous Catheter Infections in Patients with Pulmonary Arterial Hypertension
Author: Bloor, C. ; Portik, A.M. ; Julian, D. ; D'Albini, L. ; Mager, D.
01 Nov 2015·Journal of Infusion Nursing
Multiple Endocrine Neoplasia Syndromes
Review
Author: Clark, Pamela
Multiple endocrine neoplasia (MEN) is a term used to describe a group of hereditary carcinoma syndromes. Patients carrying a characteristic autosomal dominant gene aberration exhibit various endocrine carcinomas, as well as other anatomical abnormalities. Unfortunately, familial endocrine carcinoma patients are too often unrecognized by primary care providers, resulting in delayed diagnosis and treatment, with profound consequences related to morbidity and mortality. This article will introduce the various MEN syndromes and the infusion nurse's role in the care of these individuals and their families.
100 Deals associated with Accredo Health Group, Inc.
100 Translational Medicine associated with Accredo Health Group, Inc.
